2
Clinical Trials associated with Anti-CD19-CAR T cell therapy(Kecellitics Biotech Company Ltd)Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Leukemia
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
CD19 Chimeric Antigen Receptor T Cells for Treatment of Refractory/Relapsed B Lymphoid Study on the relationship between drug dosage, cell dynamics and curative effect in blood diseases
Start Date25 Sep 2020 |
Sponsor / Collaborator- |
100 Clinical Results associated with Anti-CD19-CAR T cell therapy(Kecellitics Biotech Company Ltd)
100 Translational Medicine associated with Anti-CD19-CAR T cell therapy(Kecellitics Biotech Company Ltd)
100 Patents (Medical) associated with Anti-CD19-CAR T cell therapy(Kecellitics Biotech Company Ltd)
100 Deals associated with Anti-CD19-CAR T cell therapy(Kecellitics Biotech Company Ltd)